<DOC>
	<DOCNO>NCT00399971</DOCNO>
	<brief_summary>Our hypothesis ex vivo activate immune cell would produce multiple know unknown potent hematopoietic cytokine , work concert , cytokine help stem cell growth differentiation . Additionally , cell travel home bone marrow well spleen liver involve hematopoietic activity , direct cell-cell contact may beneficial .</brief_summary>
	<brief_title>Safety Efficacy Study Ex Vivo Immunotherapy Treatment Aplastic Anemia</brief_title>
	<detailed_description>Patients require stay hospital receive immunotherapy . Allogeneic peripheral blood mononuclear cell healthy donor autologous peripheral mononuclear cell alternately use treatment . Patients expect spend least 6 12 month hospital wo n't release improve significantly .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Clinical Diagnosis Idiopathic Aplastic Anemia Not Eligible Bone Marrow Transplantation Not Responsive Conventional Immunosuppressive Therapy Leukemia MDS PNH Fanconi 's Disease pregnancy Allergic Blood Product Severe Hypertension Heart Disease Liver Kidney Disease</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Idiopathic Aplastic Anemia</keyword>
	<keyword>Has Failed Conventional Immunosuppressive Therapy</keyword>
	<keyword>Not Eligible For Bone Marrow Transplantation</keyword>
	<keyword>C15.378.071.085</keyword>
</DOC>